|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300076917 |
|
最近更新日期: Date of Last Refreshed on: |
2023-10-24 11:50:10 |
|
注册时间: Date of Registration: |
2023-10-24 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
利多卡因降低髋关节置换术老年患者术后谵妄发生率:一项前瞻性、三盲、随机、对照临床研究 |
|
Public title: |
Lidocaine reduces the incidence of postoperative delirium in elderly patients undergoing hip replacement: a prospective, triple-blind, randomized, controlled clinical study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
利多卡因降低髋关节置换术老年患者术后谵妄发生率:一项前瞻性、三盲、随机、对照临床研究 |
|
Scientific title: |
Lidocaine reduces the incidence of postoperative delirium in elderly patients undergoing hip replacement: a prospective, triple-blind, randomized, controlled clinical study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
唐毅 |
研究负责人: |
唐毅 |
|
Applicant: |
Yi Tang |
Study leader: |
Yi Tang |
|
申请注册联系人电话: Applicant telephone: |
+86 151 9622 7935 |
研究负责人电话:
Study leader's |
+86 151 9622 7935 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yitangtome@163.com |
研究负责人电子邮件: Study leader's E-mail: |
yitangtome@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省南充市顺庆区人民南路97号 |
研究负责人通讯地址: |
四川省南充市顺庆区人民南路97号 |
|
Applicant address: |
No. 97, Renmin South Road, Shunqing District, Nanchong City, Sichuan Province |
Study leader's address: |
No. 97, Renmin South Road, Shunqing District, Nanchong City, Sichuan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南充市中心医院 |
||
|
Applicant's institution: |
Nanchong Central Hospital |
||
|
研究负责人所在单位: |
南充市中心医院 |
||
|
Affiliation of the Leader: |
Nanchong Central Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023年审(059)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南充市中心医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Nanchong Central Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-07-28 00:00:00 | ||
|
伦理委员会联系人: |
曾玲 |
||
|
Contact Name of the ethic committee: |
LingZeng |
||
|
伦理委员会联系地址: |
四川省南充市顺庆区人民南路97号 |
||
|
Contact Address of the ethic committee: |
No. 97, Renmin South Road, Shunqing District, Nanchong City, Sichuan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 817 271 2055 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南充市中心医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Nanchong Central Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省南充市顺庆区人民南路97号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 97, Renmin South Road, Shunqing District, Nanchong City, Sichuan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金(82201353)、四川省自然科学基金(2022NSFSC1544、2022NSFSC0700) |
||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation of China (82201353), Sichuan Natural Science Foundation of China (2022NSFSC1544, 2022NSFSC0700) |
||||||||||||||||||||||
|
研究疾病: |
手术后谵妄 |
||||||||||||||||||||||
|
Target disease: |
Postoperative delirium |
||||||||||||||||||||||
|
研究疾病代码: |
F05.800x001 |
||||||||||||||||||||||
|
Target disease code: |
F05.800x001 |
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
探讨利多卡因是否降低髋关节置换术后老年患者POD的发生率,为POD的防治提供实验依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
To explore whether lidocaine reduces the incidence of postoperative delirium in elderly patients after hip arthroplasty, and to provide an experimental basis for the prevention and treatment of postoperative delirium. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
择期接受髋关节置换手术的65岁或以上85岁以下患者,ASA分级为I-III,BMI 18-28kg/m2,知情同意参与研究的患者。 |
||||||||||||||||||||||
|
Inclusion criteria |
American Society of Anesthesiologists physical status I-III patients aged 65 years or older and under 85 years, with body mass index of 18-28kg/m2, scheduled for elective hip replacement surgery, and informed consent to participate in the study. |
||||||||||||||||||||||
|
排除标准: |
排除精神病史或在手术前基线简易精神状态检查(MMSE)中患者受高等教育得分低于24分,中等教育低于23分,初等教育低于20分,文盲低于18分;体重<40公斤或体重>100公斤;有症状的心、脑血管疾病(如难治性心衰、脑卒中等);严重肝、肾等重要器官功能不全;利多卡因过敏者的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
The score of higher education was less than 24 points, secondary education was less than 23 points, primary education was less than 20 points, and illiteration was less than 18 points in mini-mental state examination (MMSE). Body weight <40 kg or body weight > 100 kg; Symptomatic cardiovascular and cerebrovascular diseases (such as refractory heart failure, stroke, etc.); Severe liver, kidney and other important organ dysfunction; Patients who are allergic to lidocaine. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-10-30 00:00:00至 To 2024-08-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-10-30 00:00:00 至 To 2024-08-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
试验设计者根据计算机生成的区组随机化技术(www.randomization.com),以1:1的比例将患者随机分配到两组中的一组,区组大小为6。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The trial designers randomized patients to one of two groups in a 1:1 ratio with a block size of 6 according to computer-generated block randomization (www.randomization.com). |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
三盲:受试者、管理麻醉医师、数据分析员、数据收集员不清楚实验组分配情况。 |
|
Blinding: |
"Triple blind" : subjects, managing anesthesiologists, data analysts, and data collectors were not aware of the experimental group assignment." |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2025-12-31 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
December 31,2025 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |